- Chayama K, Saito S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040–3.
- Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomised, controlled trial. N Engl J Med 1989; 321: 1501–6.
- Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506–10.
- Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterol 1993; 104: 877–83.
- Lau JYN, Davis GL, Kniffen J, Qian K, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–4.
- Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–6.
- Yoshioka K, Kakumi S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293–9.
- Cooksley WGE. Interferon treatment of chronic hepatitis C with cirrhosis. J Viral Hep 1997; 4 Suppl. 1: 85–8.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995; 96: 224–30.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77–81.
- Jouët P, Roudot-thoraval F, Dhumeaux D, Metreau J. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterol 1994; 106: 686–90.
- Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, et al. A randomised controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994; 89: 681–6.
- Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5.
- Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–801.
- Ide T, Sata M, Suzuku H, Murashima S, Miyajima I, Shirachi M, et al. Evaluation of interferon treatment in cirrhotic patients with hepatitis C. Kansenshogaku Zasshi 1996; 70: 597–604.
- Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215–22.
- Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–9.
- Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391–9.
- Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19: 1337 – 41.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524–8.
- Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190: 894–9.
- Tanaka T, Kato N, Nakagawa M, Ootsuyama Y, Cho M, Nakazawa T, et al. Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res 1992; 23: 39–53.
- Kuwana K, Ichida T, Kamimura T, Ohkoshi S, Ogata N, Harada T, et al. Risk factors and effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997; 12: 149–55.
- Miyajima I, Sata M, Gondo K, Suzuki H, Tanikawa K. Interferon accumulation in cirrhotic rat liver. J Viral Hep 1996; 3: 23–7.
- Ishimura N, Fukuda R, Fukumoto S. Relationship between the intrahepatic expression of interferon-α receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver disease. J Gastroenterol Hepatol 1996; 11: 712–7.
- Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745–9.
- Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to Interferon-β therapy. Hepatology 1997; 25: 750–3.
- Zeuzem S, Lee J, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740–4.
- Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterol 1997; 113: 567–72.
- Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, et al. Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27: 72–7.
- Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV Genotype 1a or 1b. J Med Virol 1997; 53: 118–26.
- Odeberg J, Yun Z, Sönnerborg A, Weiland O, Lundeberg J. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. J Med Virol 1998; 56: 33–8.
- Sato C, Enomoto N. Mutations in the NS5A region of HCV and interferon efficacy. Gastroenterol 1998; 115: 796.
- Herion D, Hoofnagle JH. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same. Hepatology. 1997; 25: 769–71.
- Almarri A, El Dwick N, Al Kabi S, Sleem K, Rashed A, Ritter MA, et al. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum Immunol. 1998; 59: 239–42.
- Kato N, Lan KH, Ono-nita SK, Shiratori Y, Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J Virol 1997; 71: 8856–9.
- Gale MJ, Korth MJ, Tang NM, Tan S, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistence to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217–27.
Scandinavian Journal of Infectious Diseases
Volume 31, 1999 - Issue 1